Role of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Granulomatous Disease (CGD): a Report of the United States Immunodeficiency Network.

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency for which allogeneic hematopoietic stem cell transplant (HSCT) offers potential cure. Direct comparison of HSCT to non-HSCT management in the North American population was performed to identify clinical factors associated with overall survival (OS) and transplant-related survival (TRS). Retrospective review of CGD subjects enrolled in the United States Immunodeficiency Network. Survival was estimated by the Kaplan-Meier method and modeled by proportional hazards regression. We identified 507 patients (66% CYBB mutants) diagnosed in 1953-2016. Fifty underwent allogeneic HSCT. Median follow-up was 9.1years after diagnosis (0-45.8years). OS was negatively associated with CYBB mutation (HR=6.25; p=0.034) and not associated with HSCT (88% v. 85% ± HCT) (HR=1.26; p=0.65). Transplant at ≤ 14years old was associated with improved TRS (93% v. 82% at T + 60months) (HR=- 4.51; p=0.035). Patients transplanted before 15years old had fewer severe infections pre-HSCT (mean 0.95 v. 2.13; p=0.047). No mortality was reported in patients receiving stem cells from matched siblings. Infection incidence declined post-HSCT in subjects with greater than or equal to four infections pre-HSCT (p=0.0010). Compared to non-HSCT patients ≥ 15years old, post-transplant survivors had higher mean performance score (93.2 v. 85.9; p=0.0039) and lower frequency of disability (11% v. 52%; p=0.014). Allogeneic HSCT was associated with reduced infection incidence and improved functional performance, but not with a change in overall survival. Transplant-related survival was elevated in patients undergoing HSCT before 15years old. Consider HSCT prior to late adolescence in patients with severely diminished reactive oxygen intermediate synthesis, particularly if a matched sibling is available.